1184 related articles for article (PubMed ID: 36708811)
1. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
2. Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma.
Liu L; Zhang R; Deng J; Dai X; Zhu X; Fu Q; Zhang H; Tong Z; Zhao P; Fang W; Zheng Y; Bao X
Cancer Immunol Immunother; 2022 Jan; 71(1):121-136. PubMed ID: 34028567
[TBL] [Abstract][Full Text] [Related]
3. TREM2
Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
[TBL] [Abstract][Full Text] [Related]
4. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
5. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma.
Xiong Z; Chan SL; Zhou J; Vong JSL; Kwong TT; Zeng X; Wu H; Cao J; Tu Y; Feng Y; Yang W; Wong PP; Si-Tou WW; Liu X; Wang J; Tang W; Liang Z; Lu J; Li KM; Low JT; Chan MW; Leung HHW; Chan AWH; To KF; Yip KY; Lo YMD; Sung JJ; Cheng AS
Gut; 2023 Sep; 72(9):1758-1773. PubMed ID: 37019619
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
7. Single-cell and spatial transcriptomics reveal POSTN
Chen C; Guo Q; Liu Y; Hou Q; Liao M; Guo Y; Zang Y; Wang F; Liu H; Luan X; Liang Y; Guan Z; Li Y; Liu H; Dong X; Zhang X; Liu J; Xu Q
Clin Transl Med; 2023 Dec; 13(12):e1515. PubMed ID: 38115703
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma cells remodel the pro-metastatic tumour microenvironment through recruitment and activation of fibroblasts via paracrine Egfl7 signaling.
Sun B; Lei X; Cao M; Li Y; Yang LY
Cell Commun Signal; 2023 Jul; 21(1):180. PubMed ID: 37480091
[TBL] [Abstract][Full Text] [Related]
9. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
[TBL] [Abstract][Full Text] [Related]
10. Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny.
Sheng J; Zhang J; Wang L; Tano V; Tang J; Wang X; Wu J; Song J; Zhao Y; Rong J; Cheng F; Wang J; Shen Y; Wen L; He J; Zhang H; Li T; Zhang Q; Bai X; Lu Z; Liang T
Gut; 2022 Jun; 71(6):1176-1191. PubMed ID: 34253573
[TBL] [Abstract][Full Text] [Related]
11. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
12. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
Murai H; Kodama T; Maesaka K; Tange S; Motooka D; Suzuki Y; Shigematsu Y; Inamura K; Mise Y; Saiura A; Ono Y; Takahashi Y; Kawasaki Y; Iino S; Kobayashi S; Idogawa M; Tokino T; Hashidate-Yoshida T; Shindou H; Miyazaki M; Imai Y; Tanaka S; Mita E; Ohkawa K; Hikita H; Sakamori R; Tatsumi T; Eguchi H; Morii E; Takehara T
Hepatology; 2023 Jan; 77(1):77-91. PubMed ID: 35567547
[TBL] [Abstract][Full Text] [Related]
13. Emerging Role of Cancer-Associated Fibroblasts in Progression and Treatment of Hepatocellular Carcinoma.
Akkız H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835352
[TBL] [Abstract][Full Text] [Related]
14. Single-cell RNA sequencing highlights the role of PVR/PVRL2 in the immunosuppressive tumour microenvironment in hepatocellular carcinoma.
Li A; Ji B; Yang Y; Ye B; Zhu Q; Hu X; Liu Y; Zhou P; Liu J; Gao R; Zhou Q; Kang B; Jiang Y
Front Immunol; 2023; 14():1164448. PubMed ID: 37383234
[TBL] [Abstract][Full Text] [Related]
15. Integrating single-cell and bulk RNA sequencing reveals CK19 + cancer stem cells and their specific SPP1 + tumor-associated macrophage niche in HBV-related hepatocellular carcinoma.
Yang CL; Song R; Hu JW; Huang JT; Li NN; Ni HH; Li YK; Zhang J; Lu Z; Zhou M; Wang JD; Li MJ; Zhan GH; Peng T; Yu HP; Qi LN; Wang QY; Xiang BD
Hepatol Int; 2024 Feb; 18(1):73-90. PubMed ID: 38159218
[TBL] [Abstract][Full Text] [Related]
16. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
17. Bulk and single-cell transcriptome reveal the immuno-prognostic subtypes and tumour microenvironment heterogeneity in HCC.
Ji D; Lu S; Zhang H; Li Z; Wang S; Miao T; Jiang Z; Ao L
Liver Int; 2024 Apr; 44(4):979-995. PubMed ID: 38293784
[TBL] [Abstract][Full Text] [Related]
18. Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma.
Yan ZJ; Yu CT; Chen L; Wang HY
Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36882021
[TBL] [Abstract][Full Text] [Related]
19. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
20. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence.
Zhang S; Yuan L; Danilova L; Mo G; Zhu Q; Deshpande A; Bell ATF; Elisseeff J; Popel AS; Anders RA; Jaffee EM; Yarchoan M; Fertig EJ; Kagohara LT
Genome Med; 2023 Sep; 15(1):72. PubMed ID: 37723590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
